Earnings Call · Q1 FY2026·2026-05-14

Q1 26EPS -70.24%·Rev n/aQ4 25EPS -100.00%*·Rev n/aQ3 25EPS 0.00%·Rev n/aQ2 25EPS -100.00%*·Rev n/a⚠ consensus missing

FENNEC PHARMACEUTICALS INC. FENC

Robert Andrade — CHIEF FINANCIAL OFFICER

Jeffrey Hackman — Chief Executive Officer

Terry Evans — Chief Commercial Officer

+36.5%1d on move date+35.7% vs SPY3d+41.8%5d+44.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more FENC calls or request research access.

More FENC calls Browse calls Request research access